<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00626145</url>
  </required_header>
  <id_info>
    <org_study_id>00200301</org_study_id>
    <nct_id>NCT00626145</nct_id>
  </id_info>
  <brief_title>Long Term Follow-up of Autologous Bone Marrow Mononuclear Cells Therapy in STEMI</brief_title>
  <official_title>Long Term Functional Evaluation After Intracoronary Delivery of Autologous Bone Marrow Mononuclear Cells in Patients With ST-Elevation Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The benefit of current reperfusion therapies for ST-elevation myocardial infarction (STEMI)
      is limited by post-infarction left ventricular (LV) dysfunction. Many clinic trails showed
      the short term outcome of bone marrow stem cell transplantation for MI patients, but rare
      report of long term follow-up results. Our aim was to investigate 4 years' efficacy and LV
      functional improvement of autologous bone marrow mononuclear cells (BMMC) transplantation in
      patients with ST-elevation myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The benefit of current reperfusion therapies for ST-elevation myocardial infarction (STEMI)
      is limited by post-infarction left ventricular (LV) dysfunction. Many clinic trails showed
      the short term outcome of bone marrow stem cell transplantation for MI patients, but rare
      report of long term follow-up results.

      Aim is to evaluate the long term efficiency of unselected bone marrow mononuclear cells in
      treatment of patients with ST-elevation myocardial infarction (STEMI), especially with regard
      to the left ventricular function. The cells are delivered by intracoronary infusion 7 days
      after the PCI. Outcomes including LVEF, myocardial viability and coronary artery status are
      assessed by echocardiography, SPECT and coronary angiography.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <completion_date type="Anticipated">March 2008</completion_date>
  <primary_completion_date type="Anticipated">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Ejection Fraction(LVEF)</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>in-stent restenosis</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiac shock</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>myocardial viability of the infarcted area</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>end-diastolic Volume/end-systolic Volume(EDV/ESV)</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>wall motion score index(WMSI)</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cumulative MACE(including cardiac death, non-fetal myocardial infarction and target lesion revascularization)</measure>
    <time_frame>1, 3, 6 months, 1, 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients receive intracoronary injections of saline 7 days after PCI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>saline infusion</intervention_name>
    <description>Patients receive intracoronary injections of saline 7 days after PCI.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>saline placebo</other_name>
    <other_name>placebo control</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autologous bone marrow mononuclear cells infusion</intervention_name>
    <description>Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>autologous BMMC infusion</other_name>
    <other_name>autologous bone marrow mononuclear cells transplantation</other_name>
    <other_name>autologous BMMC intracoronary injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ST segment elevation myocardial infarction, according to the WHO definition.

          -  &lt;24 hour from the origin of symptoms.

          -  Single left anterior descending coronary artery disease.

          -  Successful revascularization of culprit lesion with PCI.

          -  Age between 45 and 65 years old.

          -  Written informed consent.

        Exclusion Criteria:

          -  Previous MI.

          -  Cardiomyopathy.

          -  Atrial fibrillation or fluctuation.

          -  Previous heart surgery.

          -  Severe valvular heart disease.

          -  Disease of the hematopoetic system.

          -  NYHA functional class IV at baseline.

          -  Severe renal, lung and liver disease or cancer.

          -  Significant coronary lesion in one or more major coronary vessels, requiring
             revascularization.

          -  Intra-cardiac thrombus.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Haichang Wang, MD,PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xijing Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology in Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2008</study_first_submitted>
  <study_first_submitted_qc>February 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 29, 2008</study_first_posted>
  <last_update_submitted>February 28, 2008</last_update_submitted>
  <last_update_submitted_qc>February 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Haichang Wang / Director of Department of Cardiology of Xijing Hospital</name_title>
    <organization>Xijing Hospital of Fourth Military Medical University</organization>
  </responsible_party>
  <keyword>BMMNC</keyword>
  <keyword>STEMI</keyword>
  <keyword>stem cell</keyword>
  <keyword>intracoronary delivery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

